Chongqing pharmaceutical intends to route through St Jianfeng listed Fosun Pharmaceutical or benefit yuanmu

0 Comment

Chongqing pharmaceutical intends to route through *ST Jianfeng listed Fosun Pharmaceutical and other benefit or hot column capital flows thousands of thousands of stocks the latest Rating Rating diagnosis simulated trading client sina finance App: Live on-line blogger to tutor Sina Hong Kong APP: real time market exclusive reference is worthwhile to invest in Hong Kong stocks? What’s the problem? Where is the future of the way out? Sina launched the "Hong Kong Hong Kong stocks as well as unattractive" discussion, with a rational and constructive attitude, welcome attention to Hong Kong stocks, concern of the capital market, Hong Kong stocks together for suggestions, seek the Hong Kong stock market tomorrow. Please to hkstock_biz@sina. Chongqing Jianfeng pharmaceutical route through *ST to visit the capital market restructuring path each reporter Yan Yinchan concern is clear. In September 12th, *ST Jianfeng released the restructuring plan, the proposed price of 1 billion 493 million yuan to sell all chemical assets to the controlling shareholder of Jianfeng group, and 5.93 yuan of shares issued 1 billion 130 million shares, at a price of 6 billion 698 million yuan acquisition of the actual control of its 96.59% stake in Chongqing pharmaceutical. After the completion of the transaction, its main business will also be transformed into a pharmaceutical chemical business circulation, the actual controller is still Chongqing sasac. The "daily economic news" reporter noted that Chongqing pharmaceutical business IPO market for many years, as early as 2011 was proposed, but was shelved in 2013; and proposed to raise HK $1 billion for stock exchange main board listed in Hong Kong, due to changes in the market and run aground. In August last year, including Baiyun Mountain, Fosunpharma all carried out a strategic investment in Chongqing pharmaceutical. The analysis thinks, *ST Jianfeng smooth implementation after the reorganization, Fosun Pharmaceutical and Baiyun Mountain will get millions of dollars in investment income. In addition, *ST in Jianfeng, since the first half of this year, a loss of 312 million yuan, if the second half is not profitable, and restructuring is not completed before the end of the year, or will not escape the fate of the suspension of listing. Transaction price of nearly 6 billion 700 million yuan trapped in the industry dragged down the need to build high-quality assets *ST boost morale. Following the April 1st this year to disclose the assets of the underlying assets of the industry as the pharmaceutical industry, *ST Jianfeng also announced in September 12th a detailed restructuring plan. *ST Jianfeng Dongling international intends to 7 million 69 thousand shares of restricted shares other than in addition to the sale of all assets and liabilities have, the counterparty is the controlling shareholder of Jianfeng group, as of the valuation date March 31, 2016, the pre assessment part of the assets value of 1 billion 493 million yuan. At the same time, *ST Jianfeng intends to promote the medical group, Shenzhen Mao industry and other non-public offering of shares of 22 pharmaceutical companies in Chongqing, the purchase of its total holdings of Chongqing pharmaceutical shares of 96.59%. Chongqing pharmaceutical 100% shares pre evaluation value of $6 billion 935 million, the underlying asset transaction price initially identified as $6 billion 698 million. The issue price of shares 5.93 yuan shares, the number of shares issued is approximately 1 billion 130 million shares. Daily economic news reporter noted that after the completion of the transaction, the total share capital of listed companies is expected to be 599 million shares相关的主题文章: